Adverum randomizes first patient in Phase 2 diabetic macular edema study

Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ:ADVM) randomized the first patient in its INFINITY clinical trial evaluating ADVM-022 for the treatment of diabetic macular edema (DME).

ADVM-022 is a one-time intravitreal gene therapy designed to provide long-term efficacy and reduce the burden of frequent anti-VEGF injections.

The trial will enroll some 33 patients to demonstrate superior control of disease activity, measured by time to worsening of DME disease activities, following a single intravitreal injection of ADVM-022, compared with a single injection of aflibercept. 

“The current gold-standard therapy for DME is burdensome and often not possible clinical practice around the world, as patients require frequent, long-term anti-VEGF intravitreal injections,” Dr. Arshad Khanani, the study’s principal investigator, said in a statement.

“Based on the transformative data presented to date in the ongoing OPTIC trial for wet age-related macular degeneration, I believe that, with a single intravitreal injection, ADVM-022 has the potential to change the treatment paradigm and improve outcomes for patients with DME,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.